Characterisation and application of recombinant FVIII‐neutralising antibodies from haemophilia A inhibitor patients
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17227
Abstract: The development of anti‐drug antibodies (ADAs) is a serious outcome of treatment strategies involving biological medicines. Coagulation factor VIII (FVIII) is used to treat haemophilia A patients, but its immunogenicity precludes a third of severe… read more here.
Keywords: application recombinant; fviii; characterisation application; fviii neutralising ... See more keywords